Evidence map›Paper›PMID 25485536›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2015

Epigenetic modulation of the muscarinic type 3 receptor in salivary epithelial cells.

Yong-Hwan Shin, Meihong Jin, Sung-Min Hwang, Seul-Ki Choi, Eun Namkoong, Minkyoung Kim, Moon-Yong Park, Se-Young Choi, Jong-Ho Lee, Kyungpyo Park

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Epigenetic alteration of the purinergic type 7 receptor in salivary epithelial cells.Biochemical and biophysical research communications · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yong-Hwan ShinDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Meihong JinDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Sung-Min HwangDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Seul-Ki ChoiDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Eun NamkoongDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Minkyoung KimDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Moon-Yong ParkDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Se-Young ChoiDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Jong-Ho LeeOral and Maxillofacial Surgery, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Kyungpyo ParkDepartment of Physiology, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Korea.
Seoul National University Dental Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscarinic receptors, particularly the type 3 subtype (M3R), have an important role in exocrine secretion. M3R normally function in HSG cells originated from human submandibular gland ducts, but not in A253 and SGT cells, derived from human submandibular carcinoma and salivary gland adenocarcinoma. However, the underlying mechanism of this suppression has remained elusive. In this study, we examined whether M3R function is suppressed by epigenetic modulation of the receptor. To this end, we investigated the mRNA transcript and protein levels of the M3R using reverse transcriptase-PCR, western blot, and confocal microscopy analyses. Global DNA methylation assays, methylation-specific PCR, and bisulfite sequencing were also performed to understand the epigenetic status of the M3R CpG island. We found that A253 cells expressed all subtypes of muscarinic receptors, except M3R, on the mRNA level. However, treatment of cells with 5-aza-2'-deoxycytidine (5-Aza-CdR), a DNA-demethylating agent, increased the expression levels of both M3R mRNA transcript and protein in proportion to the incubation period. 5-Aza-CdR completely restored the carbachol-induced calcium response, which was not observed in untreated A253 cells. In untreated A253 cells, all CG pairs from the 1st to 14th were methylated and 5-Aza-CdR treatment demethylated one of the methylated CG pairs. We also examined the methylation pattern of M3R CpG island in human cancer tissue. Interestingly, the result was very similar to those of A253 cells. All CG pairs in M3R CpG island were also methylated. Another salivary gland tumor cell line, SGT, also showed the similar methylation pattern, heavy methylation in M3R CpG island. It is concluded that CpG island in M3R is hypermethylated in cancer cell lines and human cancer. Our results further suggest that 5-Aza-CdR could potentially be used to restore the function of M3R, suppressed in some cancer cell types.

Indexed as

Amino Acid SequenceAzacitidineBase SequenceBlotting, WesternCell LineCpG IslandsDecitabineDNA MethylationDNA PrimersEpigenesis, GeneticEpithelial CellsGene Expression RegulationHumansMicroscopy, ConfocalMolecular Sequence DataReceptor, Muscarinic M3AzacitidineDecitabineDNA PrimersReceptor, Muscarinic M3

Identifiers

PMID25485536
OpenAlexW2007517995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.